Test article concentrations in the hERG assay: Losses through the perfusion, solubility and stability

Journal of Pharmacological and Toxicological Methods

Volumn 59, Issue 1, 2009, Pages 29-34

  Brimecombe, Jessica C ^a   Kirsch, Glenn E ^a   Brown, Arthur M ^a  

^a ChanTest Corporation   (United States)

Author keywords

Dose solution analysis; hERG; Preclinical methods; Purkinje; Solubility; Stability

Indexed keywords

POTASSIUM CHANNEL HERG;

ARTICLE; ASSAY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SAFETY; GOOD LABORATORY PRACTICE; HUMAN; HUMAN CELL; IC 50; LONG QT SYNDROME; PERFUSION; PROTEIN FUNCTION; SOLUBILITY;

BUFFERS; DIMETHYL SULFOXIDE; ELECTROPHYSIOLOGY; ETHANOL; ETHER-A-GO-GO POTASSIUM CHANNELS; EVALUATION STUDIES AS TOPIC; HUMANS; PERFUSION; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; REFERENCE STANDARDS; SOLUTIONS; SOLVENTS; VALIDATION STUDIES AS TOPIC; VEHICLES;

EID: 58149461826     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2008.10.004     Document Type: Article

References (19)

1. Brown A.M., and Rampe D. Drug-induced long QT syndrome: Is hERG the root of all evil?. Pharmaceutical News 7 (2000) 15-20
2. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., and Keating M.T. A molecular basis for cardiac arrhythmia: hERG mutations cause long QT syndrome. Cell 80 (1995) 795-803
3. Gintant G.A. Preclinical torsades-de-pointes screens: Advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk (2008). Pharmacology and Therapeutics 119 (2008) 199-209
4. Gintant G.A., Su Z., Martin R.L., and Cox B.F. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. Toxicology Pathology 34 (2006) 81-90
5. Hanson L.A., Bass A.S., Gintant G., Mittelstadt S., Rampe D., and Tomas K. ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation. Journal of Pharmacological and Toxicological Methods 54 (2006) 116-129
6. Herron W., Tower C., and Templeton A. Experiences in method development for the analysis of in vitro study solutions for content. Journal of Pharmacological and Toxicological Methods 49 (2004) 211-216
7. Iannini P.B. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opinion on Drug Safety 1 (2002) 121-128
8. Mohammad S., Zhou Z., Gong Q., and January C.T. Blockage of the hERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. American Journal of Physiology 273 (1997) H2534-2538
9. Rampe D., Roy M.L., Dennis A., and Brown A.M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel hERG. FEBS Letters 417 (1997) 28-32
10. Ray W.A., Murray K.T., Meredith S., Narasimhulu S.S., Hall K., and Stein C.M. Oral erythromycin and the risk of sudden death from cardiac causes. New England Journal of Medicine 351 (2004) 1089-1096
11. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58 (2003) 32-45
12. Roy M., Dumaine R., and Brown A.M. hERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94 (1996) 607-609
13. Kr potassium channel. Cell 81 (1995) 299-307
14. Sha V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I.J., et al. Bioanalytical method validation - A revisit with a decade of progress. Pharmaceutical Research 17 (2000) 1551-1557
15. Suessbrich H., Waldegger S., Lang F., and Busch A.E. Blockade of hERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Letters 385 (1996) 77-80
16. Vargas H.M., Qu Y., Dunn R., Schnier P., Cheetham J., and Afshari C. hERG potency estimation and dose solution analysis: What have we learned?. Safety Pharmacology Society 7th annual Meeting Abstract #36 (2007)
17. Vargas H.M., and Yu Y. hERG potency estimation and dose solution analysis: What have we learned?. Journal of Pharmacological and Toxicological Methods 58 (2008) 155
18. Weirich J., and Antoni H. Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs. Basic Research in Cardiology 93 Suppl 1 (1998) 125-132
19. Yap Y.G., and Camm A.J. Arrhythmogenic mechanisms of non-sedating antihistamines. Clinical & Experimental Allergy 29 Suppl 3 (1999) 174-181